Hopital University Jean Verdier

Bondy, France

Hopital University Jean Verdier

Bondy, France
SEARCH FILTERS
Time filter
Source Type

PubMed | Hopital University Jean Verdier, Clinique de la Rochelle, Clinique de Bois Bernard, Roche Holding AG and 3 more.
Type: Journal Article | Journal: Hernia : the journal of hernias and abdominal wall surgery | Year: 2016

A case-control study was performed to compare laparoscopic ventral hernia repair (LVHR) using the Ventralight ST lightweight surgical mesh with LVHR using other types of mesh.Adult patients undergoing intraperitoneal implantation of Ventralight ST during LVHR (Ventralight ST group; VG) over a 2-year period (2011-2013) were identified from the prospective French Hernia-Club registry. Patients undergoing elective LVHR using other types of intraperitoneal mesh in the first semester of 2013 formed the control group (CG). Patient, hernia and surgical characteristics, and postoperative outcomes after 8days, 1month, and 1year were compared between the two groups.The VG comprised 90 LVHRs in 85 patients, and the CG 86 LVHRs in 81 patients. Patient, hernia and surgical characteristics were similar between the two groups, apart from the method of mesh fixation and the number of procedures involving fascial closure. A low rate of minor complications was observed in both groups at 1month [4.4% (VG) and 2.3% (CG)], and the level of postoperative pain was similar in the two groups at Day 8 and 1month. After 1year, no complications, recurrences or cases of chronic pain had occurred in either group, and Quality-of-Life outcomes were similar. Patients rated their procedure as excellent or good in 96% (VG) and 92% (CG) of cases.Ventralight ST mesh is effective and well tolerated in LVHR, producing very low complication and recurrence rates in the short and medium term. The results are comparable to those achieved with other types of mesh.


Gillion J.-F.,Unite de Chirurgie Viscerale et Digestive | Fromont G.,Clinique de Bois Bernard | Lepere M.,Hoffmann-La Roche | Letoux N.,Clinique Jeanne d'Arc | And 38 more authors.
Hernia | Year: 2016

Purpose: A case–control study was performed to compare laparoscopic ventral hernia repair (LVHR) using the Ventralight ST™ lightweight surgical mesh with LVHR using other types of mesh. Methods: Adult patients undergoing intraperitoneal implantation of Ventralight ST™ during LVHR (Ventralight ST™ group; VG) over a 2-year period (2011–2013) were identified from the prospective French Hernia-Club registry. Patients undergoing elective LVHR using other types of intraperitoneal mesh in the first semester of 2013 formed the control group (CG). Patient, hernia and surgical characteristics, and postoperative outcomes after 8 days, 1 month, and 1 year were compared between the two groups. Results: The VG comprised 90 LVHRs in 85 patients, and the CG 86 LVHRs in 81 patients. Patient, hernia and surgical characteristics were similar between the two groups, apart from the method of mesh fixation and the number of procedures involving fascial closure. A low rate of minor complications was observed in both groups at 1 month [4.4 % (VG) and 2.3 % (CG)], and the level of postoperative pain was similar in the two groups at Day 8 and 1 month. After 1 year, no complications, recurrences or cases of chronic pain had occurred in either group, and Quality-of-Life outcomes were similar. Patients rated their procedure as excellent or good in 96 % (VG) and 92 % (CG) of cases. Conclusions: Ventralight ST™ mesh is effective and well tolerated in LVHR, producing very low complication and recurrence rates in the short and medium term. The results are comparable to those achieved with other types of mesh. © 2016 Springer-Verlag France


Amathieu R.,Hopital University Jean Verdier | Amathieu R.,University of Paris 13 | Triba M.N.,University of Paris 13 | Goossens C.,University of Paris 13 | And 5 more authors.
World Journal of Gastroenterology | Year: 2016

Metabolomics is defined as the quantitative measurement of the dynamic multiparametric metabolic response of living systems to pathophysiological stimuli or genetic modification. It is an "omics" technique that is situated downstream of genomics, transcriptomics and proteomics. Metabolomics is recognized as a promising technique in the field of systems biology for the evaluation of global metabolic changes. During the last decade, metabolomics approaches have become widely used in the study of liver diseases for the detection of early biomarkers and altered metabolic pathways. It is a powerful technique to improve our pathophysiological knowledge of various liver diseases. It can be a useful tool to help clinicians in the diagnostic process especially to distinguish malignant and non-malignant liver disease as well as to determine the etiology or severity of the liver disease. It can also assess therapeutic response or predict drug induced liver injury. Nevertheless, the usefulness of metabolomics is often not understood by clinicians, especially the concept of metabolomics profiling or fingerprinting. In the present work, after a concise description of the different techniques and processes used in metabolomics, we will review the main research on this subject by focusing specifically on in vitro proton nuclear magnetic resonance spectroscopy based metabolomics approaches in human studies. We will first consider the clinical point of view enlighten physicians on this new approach and emphasis its future use in clinical "routine". © The Author(s) 2016.


Monnier L.,Montpellier University | Dejager S.,Novartis | Serusclat P.,Groupe Hospitalier Mutualiste Les Portes du Sud | Petit C.,Center Hospitalier Sud Francilien | And 8 more authors.
Medecine des Maladies Metaboliques | Year: 2014

Aim: To compare continuous glucose monitoring (CGM) profiles on vildagliptin vs. sitagliptin given as add-on to metformin, in patients with inadequately controlled type 2 diabetes mellitus (HbA1c 6.5-8.0%). Methods: A multicenter, prospective, randomised, open-label study with blinded analysis of the primary endpoint (CGM data, with glucose variability - mean amplitude of glucose excursions [MAGE] and standard deviation around the mean blood glucose concentration - and daily glycemic control). CGM data acquired over 3 days - firstly on metformin alone and then 8 weeks after the addition of either vildagliptin (n=14) or sitagliptin (n=16) - were centrally analyzed. Results: In comparable populations with a mean baseline HbA1c of 7.1%, 24-h glucose variability showed similar improvement on both drugs vs. metformin alone. In contrast, a series of predefined parameters reflecting daily glycemic control - mean 24-h blood glucose concentration and times spent within the optimal glycemic range (70-140 mg/dL) and above the hyperglycemic thresholds of 140 and 180 mg/dL together with the corresponding AUC values - were significantly improved from baseline only in the vildagliptin arm. In addition, overall hyperglycemia (AUC24h ≥100 mg/dL) significantly dropped from baseline on vildagliptin (-37%) but not on sitagliptin (-9%). Postprandial hyperglycemia (AUC0-4hx3) was significantly reduced on both drugs whilst basal hyperglycemia was reduced only on vildagliptin (-41% vs. baseline; P= 0.04]). Conclusion: The addition of each DPP-4 inhibitor significantly reduced glycemic variability with no difference between the two drugs. However, vildagliptin was associated with better circadian glycemic control than sitagliptin and with a significant decrease in overall hyperglycemia, mainly driven by a reduction in basal hyperglycemia. © 2014 - Elsevier Masson SAS.


PubMed | Hopital University Jean Verdier
Type: Journal Article | Journal: World journal of gastroenterology | Year: 2016

Metabolomics is defined as the quantitative measurement of the dynamic multiparametric metabolic response of living systems to pathophysiological stimuli or genetic modification. It is an omics technique that is situated downstream of genomics, transcriptomics and proteomics. Metabolomics is recognized as a promising technique in the field of systems biology for the evaluation of global metabolic changes. During the last decade, metabolomics approaches have become widely used in the study of liver diseases for the detection of early biomarkers and altered metabolic pathways. It is a powerful technique to improve our pathophysiological knowledge of various liver diseases. It can be a useful tool to help clinicians in the diagnostic process especially to distinguish malignant and non-malignant liver disease as well as to determine the etiology or severity of the liver disease. It can also assess therapeutic response or predict drug induced liver injury. Nevertheless, the usefulness of metabolomics is often not understood by clinicians, especially the concept of metabolomics profiling or fingerprinting. In the present work, after a concise description of the different techniques and processes used in metabolomics, we will review the main research on this subject by focusing specifically on in vitro proton nuclear magnetic resonance spectroscopy based metabolomics approaches in human studies. We will first consider the clinical point of view enlighten physicians on this new approach and emphasis its future use in clinical routine.

Loading Hopital University Jean Verdier collaborators
Loading Hopital University Jean Verdier collaborators